HK1100121A1 - Malaria prime/boost vaccines - Google Patents

Malaria prime/boost vaccines

Info

Publication number
HK1100121A1
HK1100121A1 HK07108068.3A HK07108068A HK1100121A1 HK 1100121 A1 HK1100121 A1 HK 1100121A1 HK 07108068 A HK07108068 A HK 07108068A HK 1100121 A1 HK1100121 A1 HK 1100121A1
Authority
HK
Hong Kong
Prior art keywords
prime
malaria
boost
boost vaccines
regimens
Prior art date
Application number
HK07108068.3A
Other languages
English (en)
Inventor
Maria Grazia Pau
Jaap Goudsmit
Joseph D Cohen
Patrice M Dubois
V Ann Stewart
Donald Heppner
Original Assignee
Crucell Holland Bv
Glaxosmithkline Biolog Sa
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Glaxosmithkline Biolog Sa, Us Government filed Critical Crucell Holland Bv
Publication of HK1100121A1 publication Critical patent/HK1100121A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK07108068.3A 2004-10-14 2007-07-25 Malaria prime/boost vaccines HK1100121A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61905604P 2004-10-14 2004-10-14
EP04105035 2004-10-14
PCT/EP2005/055209 WO2006040334A1 (fr) 2004-10-14 2005-10-13 Vaccins contre la malaria du type primo-immunisation/rappel ('prime/boost')

Publications (1)

Publication Number Publication Date
HK1100121A1 true HK1100121A1 (en) 2007-09-07

Family

ID=34929701

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07108068.3A HK1100121A1 (en) 2004-10-14 2007-07-25 Malaria prime/boost vaccines

Country Status (25)

Country Link
US (3) US20080131461A1 (fr)
EP (1) EP1802336B1 (fr)
JP (1) JP5108521B2 (fr)
KR (1) KR20070104881A (fr)
CN (1) CN101068568B (fr)
AT (1) ATE523205T1 (fr)
AU (1) AU2005293572B2 (fr)
BR (1) BRPI0518146A (fr)
CA (1) CA2582455A1 (fr)
CY (1) CY1112749T1 (fr)
DK (1) DK1802336T3 (fr)
EA (1) EA016648B1 (fr)
ES (1) ES2371175T3 (fr)
HK (1) HK1100121A1 (fr)
HR (1) HRP20110786T1 (fr)
IL (2) IL182357A0 (fr)
MA (1) MA29212B1 (fr)
MX (1) MX2007004031A (fr)
NO (1) NO20072470L (fr)
NZ (1) NZ583291A (fr)
PL (1) PL1802336T3 (fr)
PT (1) PT1802336E (fr)
RS (1) RS52187B (fr)
SI (1) SI1802336T1 (fr)
WO (1) WO2006040334A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122614A0 (en) 1995-06-15 1998-08-16 Introgene Bv Packaging systems for human recombinant adenovirus to be used in gene therapy
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
ATE384785T1 (de) * 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
WO2004055187A1 (fr) 2002-12-17 2004-07-01 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
KR20070104881A (ko) * 2004-10-14 2007-10-29 크루셀 홀란드 비.브이. 말라리아 프라임/부스트 백신
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
WO2007110409A1 (fr) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprenant un adénovirus recombiné et un adjuvant
US9717788B2 (en) * 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
UY31285A1 (es) 2007-08-13 2009-03-31 Vacunas
DK2220241T3 (en) 2007-11-28 2017-01-09 Univ Pennsylvania Adenovirus comprising a simian adenovirus E-SAdV-39-capsidhexonprotein and uses thereof
HUE031636T2 (en) 2007-11-28 2017-07-28 Univ Pennsylvania SAdV-28,27, -29, -32, -33, and -34 simian B subgenus adenoviruses
AR069568A1 (es) * 2007-12-06 2010-02-03 Glaxosmithkline Biolog Sa Vacuna de la malaria que emplea vectores adenovirales recombinantes
JP5661476B2 (ja) 2008-03-04 2015-01-28 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−３６、−４２．１、−４２．２および−４４ならびにそれらの用途
US8444996B2 (en) * 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
PL2350268T3 (pl) * 2008-11-03 2015-05-29 Crucell Holland Bv Sposób wytwarzania wektorów adenowirusowych
SG177655A1 (en) 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
CN103370411B (zh) * 2010-12-14 2016-05-04 美国卫生和人类服务部 腺病毒血清型26和血清型35线状病毒疫苗
CA2832307A1 (fr) * 2011-04-08 2012-10-18 Immune Design Corp. Compositions immunogenes et leurs procedes d'utilisation pour induire des reponses immunitaires humorales et cellulaires
SG11201404711WA (en) 2012-02-16 2014-09-26 Vlp Therapeutics Llc Virus like particle composition
BR112014028684A2 (pt) 2012-05-18 2017-07-25 Univ Pennsylvania subfamília e adenovírus de símio a1302, a1320, a1331 e a1337 e usos dos mesmos
WO2014196648A1 (fr) * 2013-06-03 2014-12-11 Vlp Therapeutics, Llc Vaccin contre le paludisme
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP3160999B1 (fr) 2014-06-26 2018-11-28 Janssen Vaccines & Prevention B.V. Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
TWI720946B (zh) 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
AU2015313650B2 (en) 2014-09-11 2021-07-08 Vlp Therapeutics, Inc. Flavivirus virus like particle
JPWO2016059911A1 (ja) * 2014-10-17 2017-07-27 国立大学法人金沢大学 マラリアワクチン
EP3600399A4 (fr) * 2017-03-30 2021-03-24 The United States of America, as represented by the Secretary of the Navy Procédés et compositions pour vacciner contre le paludisme
JP7454320B2 (ja) * 2018-02-22 2024-03-22 ターンストーン リミテッド パートナーシップ アジュバントとしての腫瘍溶解性ウイルス
CA3118034A1 (fr) * 2018-12-21 2020-06-25 Curevac Ag Arn pour vaccins antipaludiques
EP4126028A1 (fr) 2020-03-27 2023-02-08 Svenska Vaccinfabriken Produktion AB Compositions et méthodes de traitement et de prévention des coronavirus
US20230295244A1 (en) 2021-09-29 2023-09-21 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
DE69228698T2 (de) * 1991-11-16 1999-09-16 Smithkline Beecham Biologicals S.A., Rixensart HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ATE384785T1 (de) * 2001-12-07 2008-02-15 Crucell Holland Bv Herstellung von viren, virusisolaten, und impfstoffen
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (fr) * 2002-10-23 2005-07-20 Crucell Holland B.V. Nouveaux parametres pour vaccins a base d'adenoviraux recombinants
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
WO2004055187A1 (fr) * 2002-12-17 2004-07-01 Crucell Holland B.V. Vaccins contre la malaria a base virale recombinante
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
KR20070104881A (ko) * 2004-10-14 2007-10-29 크루셀 홀란드 비.브이. 말라리아 프라임/부스트 백신
EP1812067B1 (fr) * 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions contre le coronavirus du sras et utilisations de ces compositions

Also Published As

Publication number Publication date
US20090285879A1 (en) 2009-11-19
EA016648B1 (ru) 2012-06-29
CN101068568B (zh) 2012-09-26
CN101068568A (zh) 2007-11-07
PT1802336E (pt) 2011-11-15
AU2005293572B2 (en) 2011-08-04
ATE523205T1 (de) 2011-09-15
WO2006040334A1 (fr) 2006-04-20
BRPI0518146A (pt) 2008-10-28
EA200700849A1 (ru) 2007-10-26
KR20070104881A (ko) 2007-10-29
CA2582455A1 (fr) 2006-04-20
JP5108521B2 (ja) 2012-12-26
IL214460A0 (en) 2011-09-27
PL1802336T3 (pl) 2012-03-30
NO20072470L (no) 2007-07-16
RS52187B (en) 2012-10-31
NZ583291A (en) 2011-06-30
SI1802336T1 (sl) 2012-01-31
US20120014994A1 (en) 2012-01-19
ES2371175T3 (es) 2011-12-28
JP2008516926A (ja) 2008-05-22
DK1802336T3 (da) 2011-11-14
IL182357A0 (en) 2007-07-24
HRP20110786T1 (hr) 2011-12-31
US20080131461A1 (en) 2008-06-05
CY1112749T1 (el) 2016-02-10
EP1802336B1 (fr) 2011-09-07
AU2005293572A1 (en) 2006-04-20
MA29212B1 (fr) 2008-02-01
EP1802336A1 (fr) 2007-07-04
MX2007004031A (es) 2007-11-08

Similar Documents

Publication Publication Date Title
IL214460A0 (en) Malaria prime/boost vaccines
SG156535A1 (en) Recombinant viral-based malaria vaccines
WO2007008918A3 (fr) Vaccins de virus comprenant des proteines immunomodulatrices reliees a une enveloppe, et methode d'utilisation associee
WO2007027860A3 (fr) Vaccins contre la malaria a base de vecteurs adenoviraux
MX2009009342A (es) Metodo novedoso y composiciones.
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
HK1091217A1 (en) Tuberculosis vaccine with improved efficacy
WO2018193063A3 (fr) Nouveaux vaccins contre le paludisme et anticorps se liant aux sporozoïtes de plasmodium
MA30581B1 (fr) Vaccin viral recombinant
WO2006039045A3 (fr) Methode d'utilisation de vecteurs adenoviraux presentant une immunogenicite accrue in vivo
WO2006115843A3 (fr) Vaccins contre le virus nipah
WO2006029887A3 (fr) Vaccins
WO2009117656A3 (fr) Antigène incorporé dans la capside pour nouveau vaccin à adénovirus
EP2264058A3 (fr) Antigènes contre Plasmodium au niveau du foie
WO2008086386A3 (fr) Vaccins antipaludéens à base de vecteur adénoviral
WO2005007673A3 (fr) Peptides immunogenes
WO2003011331A3 (fr) Matieres et techniques relatives a des strategies de vaccination ameliorees
MX354752B (es) Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
NZ596223A (en) Combined measles-malaria vaccine
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
SG169325A1 (en) Promoters for expression in modified vaccinia virus ankara
WO2003093298A3 (fr) Peptides immunogenes
WO2002092628A3 (fr) Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques
WO2012027473A3 (fr) Compositions immunogènes comprenant des antigènes de la protéine e du virus de la dengue à vecteurs d'alphavirus

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151013